Brian J Isetts1, Daniel E Buffington2, Barry L Carter3,4, Marie Smith5, Linnea A Polgreen6, Paul A James7. 1. Department of Pharmaceutical Care & Health Systems, University of Minnesota College of Pharmacy, Minneapolis, Minnesota. 2. College of Medicine and Pharmacy, University of South Florida, Tampa, Florida. 3. The Patrick E. Keefe Professor in Pharmacy, The Department of Pharmacy Practice and Science College of Pharmacy, and Professor, The University of Iowa, Iowa City, Iowa. 4. Department of Family Medicine, The Roy J. and Lucille A. Carver College of Medicine, The University of Iowa, Iowa City, Iowa. 5. Henry A. Palmer, Professor at the University of Connecticut School of Pharmacy, Storrs, Connecticut. 6. Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, Iowa. 7. The Donald J. and Anna M. Ottilie Chair and Professor in the Department of Family Medicine, University of Iowa, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa.
Abstract
STUDY OBJECTIVE: Physician-pharmacist collaborative models have been shown to improve the care of patients with numerous chronic medical conditions. Team-based health care using integrated clinical pharmacists provides one opportunity to improve quality in health care systems that use population-based financing. In November 2015, the Centers for Medicare and Medicaid Services (CMS) requested that the relative value of pharmacists' work in team-based care needs to be established. Thus the objective of this study was to describe the components of pharmacists' work in the management of hypertension with a physician-pharmacist collaborative model. DESIGN: Descriptive analysis of the components of pharmacists' work in the Collaboration Among Pharmacists and Physicians to Improve Outcomes Now (CAPTION) study, a prospective, cluster randomized trial. MEASUREMENTS AND MAIN RESULTS: This analysis was intended to provide policymakers with data and information, using the CAPTION study model, on the time and intensity of pharmacists' work to understand pharmacists' relative value contributions in the context of CMS financing and population management aims. The CAPTION trial was conducted in 32 community-based medical offices in 15 U.S. states and included 390 patients with multiple cardiovascular risk factors. Blood pressure was measured by trained study coordinators in each office, and patients were included in the study if they had uncontrolled blood pressure. Included patients were randomized to a 9-month intervention, a 24-month intervention, or usual care. The goal of the pharmacist intervention was to improve blood pressure control and resolve drug therapy problems impeding progress toward blood pressure goals. This intervention included medical record review, a structured assessment with the patient, collaboration to achieve goals of therapy, and patient follow-up. The two intervention arms (9 and 24 mo) were identical the first 9 months, and that time frame is the focus of this workload evaluation. Pharmacists completed study encounter forms for every patient encounter and estimated time spent in pre-visit, face-to-face care, and post-visit activities. Among the 390 patients, there were 2811 encounters with pharmacists that involved 3.44 hours/patient for face-to-face care visits plus 1.55 hours/patient for pre-visit and post-visit work. Intensity of work was reflected in interventions to resolve drug therapy problems with patients (43% of encounters) and with physicians (1169 recommendations, of which physicians accepted 1153 [98.6%]), resulting in improvement of patients' blood pressure goals achieved (from 0% at baseline to 43% at 9 months based on the primary study end point). CONCLUSION: Pharmacists provided extensive interventions to patients with hypertension. This analysis provides a framework for health systems, provider groups, and payers to measure pharmacists' work in value-based financing and population management.
RCT Entities:
STUDY OBJECTIVE: Physician-pharmacist collaborative models have been shown to improve the care of patients with numerous chronic medical conditions. Team-based health care using integrated clinical pharmacists provides one opportunity to improve quality in health care systems that use population-based financing. In November 2015, the Centers for Medicare and Medicaid Services (CMS) requested that the relative value of pharmacists' work in team-based care needs to be established. Thus the objective of this study was to describe the components of pharmacists' work in the management of hypertension with a physician-pharmacist collaborative model. DESIGN: Descriptive analysis of the components of pharmacists' work in the Collaboration Among Pharmacists and Physicians to Improve Outcomes Now (CAPTION) study, a prospective, cluster randomized trial. MEASUREMENTS AND MAIN RESULTS: This analysis was intended to provide policymakers with data and information, using the CAPTION study model, on the time and intensity of pharmacists' work to understand pharmacists' relative value contributions in the context of CMS financing and population management aims. The CAPTION trial was conducted in 32 community-based medical offices in 15 U.S. states and included 390 patients with multiple cardiovascular risk factors. Blood pressure was measured by trained study coordinators in each office, and patients were included in the study if they had uncontrolled blood pressure. Included patients were randomized to a 9-month intervention, a 24-month intervention, or usual care. The goal of the pharmacist intervention was to improve blood pressure control and resolve drug therapy problems impeding progress toward blood pressure goals. This intervention included medical record review, a structured assessment with the patient, collaboration to achieve goals of therapy, and patient follow-up. The two intervention arms (9 and 24 mo) were identical the first 9 months, and that time frame is the focus of this workload evaluation. Pharmacists completed study encounter forms for every patient encounter and estimated time spent in pre-visit, face-to-face care, and post-visit activities. Among the 390 patients, there were 2811 encounters with pharmacists that involved 3.44 hours/patient for face-to-face care visits plus 1.55 hours/patient for pre-visit and post-visit work. Intensity of work was reflected in interventions to resolve drug therapy problems with patients (43% of encounters) and with physicians (1169 recommendations, of which physicians accepted 1153 [98.6%]), resulting in improvement of patients' blood pressure goals achieved (from 0% at baseline to 43% at 9 months based on the primary study end point). CONCLUSION: Pharmacists provided extensive interventions to patients with hypertension. This analysis provides a framework for health systems, provider groups, and payers to measure pharmacists' work in value-based financing and population management.
Authors: Tyler H Gums; Barry L Carter; Gary Milavetz; Lucinda Buys; Kurt Rosenkrans; Liz Uribe; Christopher Coffey; Eric J MacLaughlin; Rodney B Young; Adrienne Z Ables; Nima Patel-Shori; Angela Wisniewski Journal: Pharmacotherapy Date: 2014-08-20 Impact factor: 4.705
Authors: Krista K Proia; Anilkrishna B Thota; Gibril J Njie; Ramona K C Finnie; David P Hopkins; Qaiser Mukhtar; Nicolaas P Pronk; Donald Zeigler; Thomas E Kottke; Kimberly J Rask; Daniel T Lackland; Joy F Brooks; Lynne T Braun; Tonya Cooksey Journal: Am J Prev Med Date: 2014-06-02 Impact factor: 5.043
Authors: Barry L Carter; Christopher S Coffey; Liz Uribe; Paul A James; Brent M Egan; Gail Ardery; Elizabeth A Chrischilles; Dixie Ecklund; Mark Vander Weg; Thomas Vaughn Journal: J Clin Hypertens (Greenwich) Date: 2013-04-01 Impact factor: 3.738
Authors: Valérie Santschi; Arnaud Chiolero; April L Colosimo; Robert W Platt; Patrick Taffé; Michel Burnier; Bernard Burnand; Gilles Paradis Journal: J Am Heart Assoc Date: 2014-04-10 Impact factor: 5.501
Authors: Shubha Bhat; Miranda Kroehl; Whitley M Yi; Jaclyn Jaeger; Angela M Thompson; H Mindy Lam; Danielle Loeb; Katy E Trinkley Journal: J Am Pharm Assoc (2003) Date: 2019-04-01
Authors: Maxwell D Anderegg; Tyler H Gums; Liz Uribe; Christopher S Coffey; Paul A James; Barry L Carter Journal: Hypertension Date: 2016-09-06 Impact factor: 10.190
Authors: Brittany Stewart; Aaron Brody; Abhinav C Krishnan; Sara K Brown; Phillip D Levy Journal: Curr Hypertens Rep Date: 2019-06-19 Impact factor: 5.369
Authors: Leslie Carstensen Floren; Jennifer Mandal; Maria Dall'Era; Jaekyu Shin; David M Irby; Olle Ten Cate; Bridget C O'Brien Journal: Am J Pharm Educ Date: 2020-02 Impact factor: 2.047
Authors: Maxwell D Anderegg; Tyler H Gums; Liz Uribe; Eric J MacLaughlin; James Hoehns; Oralia V Bazaldua; Timothy J Ives; David L Hahn; Christopher S Coffey; Barry L Carter Journal: Pharmacotherapy Date: 2018-02-23 Impact factor: 4.705
Authors: Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian Journal: J Am Coll Cardiol Date: 2019-03-17 Impact factor: 24.094
Authors: Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian Journal: J Am Coll Cardiol Date: 2019-03-17 Impact factor: 24.094
Authors: Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian Journal: Circulation Date: 2019-03-17 Impact factor: 29.690